Currently, two types of tumour immunotherapy are usually used: one is to relieve the inhibitory effect of cancer cells on immune cells by administering drugs, such as αPD-1/αPD-L1 and αCTLA-4 antibodies, an approach often compared to "releasing the brakes"[44, 45]; the other is to enhance the activity of immune cells to fight cancer by administering drugs, such as the anti-OX40 antibody and anti-41-BB antibody [46], which we often compare to "stepping on the accelerator"[47]. This evidence concerns the gene TNFRSF4 and cancer.